In their retrospective analysis of 93 BCs (25 MIBC and 68 NMIBC), three results should be highlighted: (i) the HER2 protein expression by immunohistochemistry correlated with the stage and grade of BC, (ii) progression-free survival significantly correlated with stage, grade and HER2 3+ expression, and (iii) that in the NMIBC subgroup, HER2 3+ expression and gene amplification was seen only in high-grade NMIBC, all of them being lamina-invasive (pT1). This evidence concerns the gene ERBB2 and breast cancer.